Oliver J L, Wolfe L G
Department of Pathobiology, College of Veterinary Medicine, Auburn University, AL 36849-5519.
Am J Vet Res. 1992 Jan;53(1):123-8.
A murine hybridoma monoclonal antibody (MAB), IBF9, was generated by fusing myeloma cells (P3X63Ag8.653) with spleen cells from a BALB/c mouse immunized with the canine melanoma cell line CML-10c7. Initial screening of hybridoma antibodies was performed by use of an indirect immunoperoxidase assay on formalin-fixed CML-10c7 cells. The isotype of MAB IBF9 was IgG1 as determined by radial gel immunodiffusion. The antibody was tested for reactivity against a panel of formalin-fixed, paraffin-embedded normal and neoplastic canine tissues, using immunoperoxidase staining. Immunostaining was observed in melanomas (24 of 38), a few carcinomas, basal cell tumors, and cutaneous lymphosarcomas. Immunostaining was not observed in fibrosarcomas, hemangiosarcomas, hemangiopericytomas, or histiocytomas. Staining of normal adult canine tissues was limited to a few epithelial tissues and a small percentage of lymphocytes. Fetal tissues were not reactive with MAB IBF9. There were statistically significant differences in frequency of reactivity among melanomas with regard to oral vs non-oral, malignant vs benign, and mitotic indices greater than or equal to 1 vs mitotic indices less than 1. Differences were not significant when tumors were compared for degree of pigmentation or histologic type. On the basis of these findings, we suggest that MAB IBF9 may be of assistance in diagnosis of nonpigmented melanomas and in assessing the malignant potential of melanomas.
通过将骨髓瘤细胞(P3X63Ag8.653)与用犬黑色素瘤细胞系CML-10c7免疫的BALB/c小鼠的脾细胞融合,产生了一种小鼠杂交瘤单克隆抗体(MAB)IBF9。通过对福尔马林固定的CML-10c7细胞进行间接免疫过氧化物酶测定,对杂交瘤抗体进行初步筛选。通过放射状凝胶免疫扩散法测定,MAB IBF9的同种型为IgG1。使用免疫过氧化物酶染色法,检测该抗体对一组福尔马林固定、石蜡包埋的正常和肿瘤性犬组织的反应性。在黑色素瘤(38例中的24例)、少数癌、基底细胞瘤和皮肤淋巴瘤中观察到免疫染色。在纤维肉瘤、血管肉瘤、血管外皮细胞瘤或组织细胞瘤中未观察到免疫染色。正常成年犬组织的染色仅限于少数上皮组织和一小部分淋巴细胞。胎儿组织与MAB IBF9无反应。在黑色素瘤中,口腔与非口腔、恶性与良性以及有丝分裂指数大于或等于1与有丝分裂指数小于1之间的反应频率存在统计学显著差异。当比较肿瘤的色素沉着程度或组织学类型时,差异不显著。基于这些发现,我们认为MAB IBF9可能有助于非色素性黑色素瘤的诊断以及评估黑色素瘤的恶性潜能。